Holen Sie sich die Stockscreener-App
1.945
8.06%
0.145
Schlusskurs vom Vortag:
$1.80
Offen:
$1.94
24-Stunden-Volumen:
421.67K
Relative Volume:
0.76
Marktkapitalisierung:
$131.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.20M
KGV:
-0.9047
EPS:
-2.15
Netto-Cashflow:
$57,000
1W Leistung:
+7.46%
1M Leistung:
-13.56%
6M Leistung:
+51.95%
1J Leistung:
-64.11%
1-Tages-Spanne:
$1.82
$1.9999
1-Wochen-Bereich:
$1.54
$1.9999
52-Wochen-Spanne:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Vergleichen Sie CLYM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.945 | 121.98M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.99 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.74 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.41 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.34 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Will Climb Bio Inc. stock deliver shareholder valueJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
How to integrate Climb Bio Inc. into portfolio analysis toolsMarket Activity Report & Real-Time Stock Price Movement Reports - newser.com
Climb Bio Inc. recovery potential after sell offTake Profit & Growth Focused Stock Pick Reports - newser.com
HC Wainwright Initiates Climb Bio at Buy With $9 Price Target - MarketScreener
Climb Bio Unveils Promising Preclinical Data for CLYM116 - MSN
Can technical indicators confirm Climb Bio Inc.’s reversalEarnings Recap Summary & Fast Entry High Yield Tips - newser.com
Leading vs lagging indicators on Climb Bio Inc. performanceJuly 2025 Intraday Action & Safe Entry Point Alerts - newser.com
What technical models suggest about Climb Bio Inc.’s comebackJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Institutional scanner results for Climb Bio Inc.July 2025 Snapshot & Free Technical Pattern Based Buy Signals - newser.com
Visual analytics tools that track Climb Bio Inc. performanceQuarterly Profit Report & Community Verified Watchlist Alerts - newser.com
Relative strength of Climb Bio Inc. in sector analysisJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Climb Bio Inc. stock volume spike explainedMarket Movement Recap & AI Forecasted Entry and Exit Points - newser.com
Climb Bio (NASDAQ:CLYM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Climb Bio Inc. stock prediction for this week2025 Sector Review & Safe Entry Zone Tips - newser.com
How to use Fibonacci retracement on Climb Bio Inc.Market Trend Report & Weekly Top Stock Performers List - newser.com
Can Climb Bio Inc. stock outperform in 2025 bull market2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Sector ETF performance correlation with Climb Bio Inc.Short Setup & Real-Time Market Trend Scan - newser.com
Climb Bio, Inc. (NASDAQ:CLYM) Sees Significant Drop in Short Interest - MarketBeat
Climb Bio Experiences Measurable Shift In Market Positioning - Kalkine Media
Climb Bio (NASDAQ:CLYM) Rating Increased to Hold at Wall Street Zen - Defense World
Climb Bio (NASDAQ:CLYM) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Analyzing Climb Bio Inc. with multi timeframe charts2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Can Climb Bio Inc. recover in the next quarterMarket Risk Report & Reliable Trade Execution Plans - newser.com
Climb Bio to be Added to the Nasdaq Biotechnology Index - FinancialContent
Climb Bio appoints Susan Altschuller as new CFO By Investing.com - Investing.com Nigeria
Climb Bio appoints Susan Altschuller as chief financial officer By Investing.com - Investing.com Nigeria
Former bluebird CEO picked to lead Inventiva - BioCentury
Climb Bio appoints Susan Altschuller as chief financial officer - Investing.com India
Climb Bio Appoints New CFO Susan Altschuller - TipRanks
Climb Bio Names Dr. Susan Altschuller CFO - MarketScreener
Leerink Partners Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Climb Bio appoints Susan Altschuller, Ph.D., MBA as chief financial officer - MarketScreener
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer - markets.businessinsider.com
Climb Bio appoints Susan Altschuller as new CFO - Investing.com
From $8.7B Cerevel Deal to Climb Bio: Biotech Veteran Susan Altschuller Takes CFO Role as Trials Advance - Stock Titan
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Climb Bio Inc-Aktie (CLYM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pimblett Emily | SVP, Finance & CAO |
Jun 20 '25 |
Sale |
1.24 |
1,242 |
1,540 |
18,888 |
| Pimblett Emily | SVP, Finance & CAO |
Mar 20 '25 |
Sale |
1.31 |
1,199 |
1,571 |
15,130 |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Dec 19 '24 |
Sale |
2.02 |
1,235 |
2,495 |
11,329 |
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):